tetano
Editor, Senior Moderator
Signal Transduct Target Ther
. 2022 Feb 23;7(1):57.
doi: 10.1038/s41392-022-00907-1.
The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication
Qin Ning[SUP] #[/SUP][SUP] 1 [/SUP], Di Wu[SUP] #[/SUP][SUP] 2 [/SUP], Xiaojing Wang[SUP] 2 [/SUP], Dong Xi[SUP] 2 [/SUP], Tao Chen[SUP] 2 [/SUP], Guang Chen[SUP] 2 [/SUP], Hongwu Wang[SUP] 2 [/SUP], Huiling Lu[SUP] 3 [/SUP], Ming Wang[SUP] 2 [/SUP], Lin Zhu[SUP] 2 [/SUP], Junjian Hu[SUP] 2 [/SUP], Tingting Liu[SUP] 2 [/SUP], Ke Ma[SUP] 2 [/SUP], Meifang Han[SUP] 4 [/SUP], Xiaoping Luo[SUP] 5 [/SUP]
Affiliations
Abstract
The coronavirus disease 2019 (COVID-19) is a highly transmissible disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that poses a major threat to global public health. Although COVID-19 primarily affects the respiratory system, causing severe pneumonia and acute respiratory distress syndrome in severe cases, it can also result in multiple extrapulmonary complications. The pathogenesis of extrapulmonary damage in patients with COVID-19 is probably multifactorial, involving both the direct effects of SARS-CoV-2 and the indirect mechanisms associated with the host inflammatory response. Recognition of features and pathogenesis of extrapulmonary complications has clinical implications for identifying disease progression and designing therapeutic strategies. This review provides an overview of the extrapulmonary complications of COVID-19 from immunological and pathophysiologic perspectives and focuses on the pathogenesis and potential therapeutic targets for the management of COVID-19.
. 2022 Feb 23;7(1):57.
doi: 10.1038/s41392-022-00907-1.
The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication
Qin Ning[SUP] #[/SUP][SUP] 1 [/SUP], Di Wu[SUP] #[/SUP][SUP] 2 [/SUP], Xiaojing Wang[SUP] 2 [/SUP], Dong Xi[SUP] 2 [/SUP], Tao Chen[SUP] 2 [/SUP], Guang Chen[SUP] 2 [/SUP], Hongwu Wang[SUP] 2 [/SUP], Huiling Lu[SUP] 3 [/SUP], Ming Wang[SUP] 2 [/SUP], Lin Zhu[SUP] 2 [/SUP], Junjian Hu[SUP] 2 [/SUP], Tingting Liu[SUP] 2 [/SUP], Ke Ma[SUP] 2 [/SUP], Meifang Han[SUP] 4 [/SUP], Xiaoping Luo[SUP] 5 [/SUP]
Affiliations
- PMID: 35197452
- DOI: 10.1038/s41392-022-00907-1
Abstract
The coronavirus disease 2019 (COVID-19) is a highly transmissible disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that poses a major threat to global public health. Although COVID-19 primarily affects the respiratory system, causing severe pneumonia and acute respiratory distress syndrome in severe cases, it can also result in multiple extrapulmonary complications. The pathogenesis of extrapulmonary damage in patients with COVID-19 is probably multifactorial, involving both the direct effects of SARS-CoV-2 and the indirect mechanisms associated with the host inflammatory response. Recognition of features and pathogenesis of extrapulmonary complications has clinical implications for identifying disease progression and designing therapeutic strategies. This review provides an overview of the extrapulmonary complications of COVID-19 from immunological and pathophysiologic perspectives and focuses on the pathogenesis and potential therapeutic targets for the management of COVID-19.